BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, Deroose CM, Cleeren F. Automated GMP compliant production of [18F]AlF-NOTA-octreotide. EJNMMI Radiopharm Chem 2020;5:4. [PMID: 31997090 DOI: 10.1186/s41181-019-0084-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Deng Y, He L, Gao H, Deng Y, Zhang W. Primary Neuroendocrine Carcinoma of Pineal Gland With Extensive Meningeal Metastasis Detected by 18F-NOTATATE PET/CT. Clin Nucl Med 2022;47:1105-1107. [DOI: 10.1097/rlu.0000000000004368] [Reference Citation Analysis]
2 Dam JH, Langkjær N, Baun C, Olsen BB, Nielsen AY, Thisgaard H. Preparation and Evaluation of [18F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [68Ga]Ga-DOTA/NOTA-NOC. Molecules 2022;27:6818. [DOI: 10.3390/molecules27206818] [Reference Citation Analysis]
3 Wurzer A, Nekolla SG, D’alessandria C. Stand der Technik in der Radiopharmazie. Angewandte Nuklearmedizin 2022;45:167-188. [DOI: 10.1055/a-1715-5069] [Reference Citation Analysis]
4 Ahenkorah S, Murce E, Cawthorne C, Ketchemen JP, Deroose CM, Cardinaels T, Seimbille Y, Fonge H, Gsell W, Bormans G, Ooms M, Cleeren F. 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals. Theranostics 2022;12:5971-85. [PMID: 35966589 DOI: 10.7150/thno.75336] [Reference Citation Analysis]
5 Fu C, Yu L, Miao Y, Liu X, Yu Z, Wei M. Peptide‒drug conjugates (PDCs): A novel trend of research and development on targeted therapy, hype or hope? Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.07.020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Korde A, Mikolajczak R, Kolenc P, Bouziotis P, Westin H, Lauritzen M, Koole M, Herth MM, Bardiès M, Martins AF, Paulo A, Lyashchenko SK, Todde S, Nag S, Lamprou E, Abrunhosa A, Giammarile F, Decristoforo C. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals. EJNMMI Radiopharm Chem 2022;7:18. [PMID: 35852679 DOI: 10.1186/s41181-022-00168-x] [Reference Citation Analysis]
7 Hu K, Li J, Wang L, Huang Y, Li L, Ye S, Han Y, Huang S, Wu H, Su J, Tang G. Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts. Acta Pharm Sin B 2022;12:867-75. [PMID: 35256951 DOI: 10.1016/j.apsb.2021.09.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
8 Huang J, Fu L, Hu K, Huang S, Han Y, Lin R, Xu W, Tang G, Huang Y. Automatic Production and Preliminary PET Imaging of a New Imaging Agent [18F]AlF-FAPT. Front Oncol 2021;11:802676. [PMID: 35071007 DOI: 10.3389/fonc.2021.802676] [Reference Citation Analysis]
9 Barnes C, Nair M, Aboagye EO, Archibald SJ, Allott L. A practical guide to automating fluorine-18 PET radiochemistry using commercially available cassette-based platforms. React Chem Eng . [DOI: 10.1039/d2re00219a] [Reference Citation Analysis]
10 Luyten K, Van Loy T, Cawthorne C, Deroose CM, Schols D, Bormans G, Cleeren F. D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy. Pharmaceutics 2021;13:1619. [PMID: 34683912 DOI: 10.3390/pharmaceutics13101619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Archibald SJ, Allott L. The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules. EJNMMI Radiopharm Chem 2021;6:30. [PMID: 34436693 DOI: 10.1186/s41181-021-00141-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
12 Naka S, Watabe T, Lindner T, Cardinale J, Kurimoto K, Moore M, Tatsumi M, Mori Y, Shimosegawa E, Valla F Jr, Kato H, Giesel FL. One-pot and one-step automated radio-synthesis of [18F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment. EJNMMI Radiopharm Chem 2021;6:28. [PMID: 34420105 DOI: 10.1186/s41181-021-00142-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Gower-Fry L, Kronemann T, Dorian A, Pu Y, Jaworski C, Wängler C, Bartenstein P, Beyer L, Lindner S, Jurkschat K, Wängler B, Bailey JJ, Schirrmacher R. Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) 18F-Radiopharmaceuticals. Pharmaceuticals (Basel) 2021;14:701. [PMID: 34358127 DOI: 10.3390/ph14070701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Yu Q, Tan X, Li D, Shi B, Wu F, Xu D, Xue W, Wang Z. Automated radiosynthesis of [18F]AlF-NOTA-octreotide and PET/CT imaging in NENs. J Radioanal Nucl Chem 2021;328:825-833. [DOI: 10.1007/s10967-021-07746-4] [Reference Citation Analysis]
15 Sahnoun S, Conen P, Mottaghy FM. The battle on time, money and precision: Da[18F] id vs. [68Ga]liath. Eur J Nucl Med Mol Imaging 2020;47:2944-6. [PMID: 32715336 DOI: 10.1007/s00259-020-04961-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
16 Beyer L, Gosewisch A, Lindner S, Völter F, Mittlmeier LM, Tiling R, Brendel M, Cyran CC, Unterrainer M, Rübenthaler J, Auernhammer CJ, Spitzweg C, Böning G, Gildehaus FJ, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Wenter V, Todica A, Bartenstein P, Ilhan H. Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2021. [PMID: 33928401 DOI: 10.1007/s00259-021-05351-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
17 Allott L, Amgheib A, Barnes C, Braga M, Brickute D, Wang N, Fu R, Ghaem-Maghami S, Aboagye EO. Radiolabelling an 18F biologic via facile IEDDA "click" chemistry on the GE FASTLab™ platform. React Chem Eng 2021;6:1070-8. [PMID: 34123410 DOI: 10.1039/d1re00117e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Xie Q, Liu T, Ding J, Zhou N, Meng X, Zhu H, Li N, Yu J, Yang Z. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2021;48:3129-40. [PMID: 33630145 DOI: 10.1007/s00259-021-05249-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
19 Al-Qahtani M, Behe M, Bormans G, Carlucci G, Dasilva J, Decristoforo C, Elsinga PH, Kopka K, Li XG, Mach R, Middel O, Passchier J, Patt M, Penuelas I, Rey A, Scott PJH, Todde S, Toyohara J, Vugts D. Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020). EJNMMI Radiopharm Chem 2021;6:5. [PMID: 33507426 DOI: 10.1186/s41181-020-00118-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Pérez DJ, Ávila-rodríguez MA. Methods to radiolabel somatostatin analogs with [18F]fluoride: current status, challenges, and progress in clinical applications. J Radioanal Nucl Chem 2020;326:1519-1542. [DOI: 10.1007/s10967-020-07437-6] [Reference Citation Analysis]
21 Lindner S, Simmet M, Gildehaus FJ, Jurkschat K, Wängler C, Wängler B, Bartenstein P, Schirrmacher R, Ilhan H. Automated production of [18F]SiTATE on a Scintomics GRP™ platform for PET/CT imaging of neuroendocrine tumors. Nucl Med Biol 2020;88-89:86-95. [PMID: 32828007 DOI: 10.1016/j.nucmedbio.2020.07.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
22 Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, Van Cutsem E, Verslype C, Van Laere K, Bormans G, Deroose CM. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging 2020;47:3033-46. [PMID: 32617641 DOI: 10.1007/s00259-020-04918-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
23 Allott L, Aboagye EO. Chemistry Considerations for the Clinical Translation of Oncology PET Radiopharmaceuticals. Mol Pharmaceutics 2020;17:2245-59. [DOI: 10.1021/acs.molpharmaceut.0c00328] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
24 Allott L, Dubash S, Aboagye EO. [18F]FET-βAG-TOCA: The Design, Evaluation and Clinical Translation of a Fluorinated Octreotide. Cancers (Basel) 2020;12:E865. [PMID: 32252406 DOI: 10.3390/cancers12040865] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
25 Hennrich U, Benešová M. [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging. Pharmaceuticals (Basel) 2020;13:E38. [PMID: 32138377 DOI: 10.3390/ph13030038] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 23.5] [Reference Citation Analysis]